Dawn Shotland
Senior Vice President, Investor Relations and Corporate Affairs
Replay available
Geron Corporation (GERN) Q4 2025 Earnings Call
Geron Corporation (NASDAQ: GERN) Q4 2025 earnings conference call, held 2026-02-25. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Harut Samarjian
Chief Executive Officer
Ahmed El-Nawawi
Chief Commercial Officer
Dr. Joseph Eade
Executive Vice President, Research and Development and Chief Medical Officer
Michelle Robertson
Chief Financial Officer
Tara Bancroft
Equity Research Analyst, TD Cowen
Gil Plum
Analyst, Needham & Company
Emily Bodnar
Equity Research Analyst, H.C. Wainwright & Co.
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Geron Corporation.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.099 Hello, and welcome to the Geron Corporation fourth quarter 2025 earnings call. 00:00:05.099 -- 00:00:08.284 At this time, all participants are in a listen-only mode. 00:00:08.284 -- 00:00:12.290 After the speaker's presentation, there will be a question and answer session. 00:00:12.290 -- 00:00:17.418 To ask a question during this session, you'll need to press star 1-1 on your telephone. 00:00:17.418 -- 00:00:21.264 You will then hear an automated message advising your hand is raised. 00:00:21.264 -- 00:00:25.571 To withdraw your question, please press star 1-1 again. 00:00:25.571 -- 00:00:29.174 Please be advised that today's conference is being recorded. 00:00:29.174 -- 00:00:33.078 I would now like to turn the call over to Dawn Shotland, Senior Vice President, Investor 00:00:33.078 -- 00:00:36.781 Relations and Corporate Affairs. You may begin. 00:00:36.781 -- 00:00:42.106 Good morning, everyone. Welcome to the Jaron Corporation fourth quarter 2025 00:00:42.106 -- 00:00:47.191 earnings conference call. Before we begin, please note that during the course of this 00:00:47.191 -- 00:00:52.416 presentation and question and answer session, we will be making forward-looking statements 00:00:52.416 -- 00:00:57.440 regarding future events, performance, plans, expectations, and other 00:00:57.440 -- 00:01:02.442 projections including those relating to our 2026 financial guidance, the 00:01:02.442 -- 00:01:07.448 expected benefits and other impacts of our strategic restructuring plan, our 00:01:07.448 -- 00:01:12.194 current VITAL commercialization strategy and related opportunities, 00:01:12.194 -- 00:01:17.520 the therapeutic potential of VITAL, other anticipated clinical and commercial events 00:01:17.520 -- 00:01:19.663 and related ti...